AU2013211850A8 - Methods for profiling and quantitating cell-free RNA - Google Patents

Methods for profiling and quantitating cell-free RNA

Info

Publication number
AU2013211850A8
AU2013211850A8 AU2013211850A AU2013211850A AU2013211850A8 AU 2013211850 A8 AU2013211850 A8 AU 2013211850A8 AU 2013211850 A AU2013211850 A AU 2013211850A AU 2013211850 A AU2013211850 A AU 2013211850A AU 2013211850 A8 AU2013211850 A8 AU 2013211850A8
Authority
AU
Australia
Prior art keywords
methods
tissue
rna
profiling
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2013211850A
Other versions
AU2013211850B2 (en
AU2013211850B8 (en
AU2013211850A1 (en
Inventor
Hei-Mun Christina Fan
Lian Chye Winston Koh
Wenying Pan
Stephen R. Quake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2013211850A1 publication Critical patent/AU2013211850A1/en
Publication of AU2013211850B2 publication Critical patent/AU2013211850B2/en
Application granted granted Critical
Publication of AU2013211850B8 publication Critical patent/AU2013211850B8/en
Publication of AU2013211850A8 publication Critical patent/AU2013211850A8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00—Pattern recognition
    • G06F18/20—Analysing
    • G06F18/21—Design or setup of recognition systems or techniques; Extraction of features in feature space; Blind source separation
    • G06F18/213—Feature extraction, e.g. by transforming the feature space; Summarisation; Mappings, e.g. subspace methods
    • G06F18/2135—Feature extraction, e.g. by transforming the feature space; Summarisation; Mappings, e.g. subspace methods based on approximation criteria, e.g. principal component analysis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Databases & Information Systems (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Public Health (AREA)
  • Bioethics (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention generally relates to methods for assessing the health of a tissue by characterizing circulating nucleic acids in a biological sample. According to certain embodiments, methods for assessing the health of a tissue include the steps of detecting a sample level of RNA in a biological sample, comparing the sample level of RNA to a reference level of RNA specific to the tissue, determining whether a difference exists between the sample level and the reference level, and characterizing the tissue as abnormal if a difference is detected.
AU2013211850A 2012-01-27 2013-01-28 Methods for profiling and quantitating cell-free RNA Active AU2013211850B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591642P 2012-01-27 2012-01-27
US61/591,642 2012-01-27
PCT/US2013/023471 WO2013113012A2 (en) 2012-01-27 2013-01-28 Methods for profiling and quantitating cell-free rna

Publications (4)

Publication Number Publication Date
AU2013211850A1 AU2013211850A1 (en) 2014-09-18
AU2013211850B2 AU2013211850B2 (en) 2017-03-02
AU2013211850B8 AU2013211850B8 (en) 2017-06-29
AU2013211850A8 true AU2013211850A8 (en) 2017-06-29

Family

ID=48874081

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013211850A Active AU2013211850B8 (en) 2012-01-27 2013-01-28 Methods for profiling and quantitating cell-free RNA

Country Status (9)

Country Link
US (14) US20130252835A1 (en)
EP (2) EP3584327A1 (en)
JP (2) JP6320302B2 (en)
CN (2) CN104334742A (en)
AU (1) AU2013211850B8 (en)
CA (1) CA2863035C (en)
HK (1) HK1211624A1 (en)
SG (2) SG10201906331TA (en)
WO (1) WO2013113012A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2318552B1 (en) 2008-09-05 2016-11-23 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
HUE052213T2 (en) 2009-11-06 2021-04-28 Univ Leland Stanford Junior Non-invasive diagnosis of graft rejection in organ transplant patients
NZ608313A (en) 2010-09-24 2013-12-20 Univ Leland Stanford Junior Direct capture, amplification and sequencing of target dna using immobilized primers
WO2015069900A1 (en) * 2013-11-06 2015-05-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiliing and quantitating cell-free rna
US20160289762A1 (en) * 2012-01-27 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiliing and quantitating cell-free rna
AU2013211850B8 (en) 2012-01-27 2017-06-29 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiling and quantitating cell-free RNA
US10689652B2 (en) 2013-10-02 2020-06-23 The Regents Of The University Of California Methods for immortalization of epithelial cells
WO2015069933A1 (en) * 2013-11-06 2015-05-14 The Board Of Trustees Of The Leland Stanford Junior University Circulating cell-free dna for diagnosis of transplant rejection
IL285106B (en) * 2013-11-07 2022-09-01 Univ Leland Stanford Junior Cell-free nucleic acids for the analysis of the human microbiome and components thereof
KR102696857B1 (en) 2014-07-25 2024-08-19 유니버시티 오브 워싱톤 Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
JP2017538404A (en) 2014-11-14 2017-12-28 リキッド ジェノミクス，インコーポレイティド Use of circulating cell-free RNA for diagnosing and / or observing cancer
CN107922971A (en) 2015-05-18 2018-04-17 凯锐思公司 Composition and method for enriched nucleic acid colony
WO2016205753A1 (en) * 2015-06-17 2016-12-22 The Translational Genomics Research Institute Systems and methods for obtaining biological molecules from a sample
US10692797B2 (en) * 2015-06-30 2020-06-23 Laird Technologies, Inc. Thermal interface materials with low secant modulus of elasticity and high thermal conductivity
WO2017062517A1 (en) * 2015-10-06 2017-04-13 The Regents Of The University Of California Non-coding rnas linked to immortality and associated methods and compositions
US10890592B2 (en) * 2015-11-04 2021-01-12 Metabolon, Inc. Automated sample quality assessment
AU2017237199B2 (en) 2016-03-25 2020-11-05 Karius, Inc. Synthetic nucleic acid spike-ins
WO2018191563A1 (en) 2017-04-12 2018-10-18 Karius, Inc. Sample preparation methods, systems and compositions
KR20200003917A (en) * 2017-05-10 2020-01-10 난토믹스, 엘엘씨 CIRCULATING RNA FOR DETECTION, PREDICTION, AND MONITORING OF CANCER
CA3062985A1 (en) * 2017-05-16 2018-11-22 The Chinese University Of Hong Kong Integrative single-cell and cell-free plasma rna analysis
US20230140653A1 (en) * 2017-10-23 2023-05-04 Chan Zuckerberg Biohub, Inc. Noninvasive molecular clock for fetal development predicts gestational age and preterm delivery
JP2021500883A (en) 2017-10-27 2021-01-14 ジュノ ダイアグノスティックス，インク． Devices, systems, and methods for ultratrace liquid biopsy
US11702703B2 (en) 2017-11-07 2023-07-18 Nanthealth Labs, Inc. Targeted cell free nucleic acid analysis
CA3082601A1 (en) 2018-03-16 2019-09-19 Karius, Inc. Sample series to differentiate target nucleic acids from contaminant nucleic acids
CA3117412A1 (en) * 2018-10-29 2020-05-07 Molecular Stethoscope, Inc. Characterization of bone marrow using cell-free messenger-rna
CA3121923A1 (en) * 2018-12-18 2020-06-25 Wenying Pan Methods for detecting disease using analysis of rna
WO2020154402A1 (en) * 2019-01-24 2020-07-30 Illumina, Inc. Methods and systems for monitoring organ health and disease
GB2615975B (en) * 2019-02-14 2023-11-29 Mirvie Inc Methods and systems for determining a pregnancy-related state of a subject
EP3947674A4 (en) * 2019-04-02 2023-06-07 Mission Bio, Inc. Methods, systems, and aparatus for nucleic acid detection
AU2020280104A1 (en) 2019-05-22 2022-01-20 Mission Bio, Inc. Method and apparatus for simultaneous targeted sequencing of DNA, RNA and protein
US11948684B2 (en) * 2019-06-20 2024-04-02 Latha Chakravarthy Diagnostic process for disease detection using gene expression based multi layer PCA classifier
CN110964800B (en) * 2019-09-20 2021-10-22 北京航空航天大学 cfRNA markers for predicting risk of preterm birth
EP4055180A4 (en) * 2019-11-05 2023-12-06 Cofactor Genomics, Inc. Methods and systems of processing complex data sets using artificial intelligence and deconvolution
EP4077710A4 (en) * 2019-12-20 2024-02-21 University of Utah Research Foundation Methods and compositions for monitoring and diagnosing healthy and disease states
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
JP2023518291A (en) * 2020-03-18 2023-04-28 モレキュラー ステソスコープ， インコーポレイテッド Systems and methods for detecting Alzheimer's disease risk using circulating free mRNA profiling assays
WO2022036053A2 (en) * 2020-08-13 2022-02-17 Mirvie, Inc. Methods and systems for determining a pregnancy-related state of a subject
WO2024182491A1 (en) * 2023-02-28 2024-09-06 Virginia Commonwealth University Polygenic risk estimator for cervical length change during pregnancy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065629A1 (en) * 2003-01-17 2004-08-05 The Chinese University Of Hong Kong Circulating mrna as diagnostic markers for pregnancy-related disorders
WO2009025852A2 (en) * 2007-08-22 2009-02-26 Xenomics, Inc. Methods of using mirna for detection of in vivo cell death
WO2011156734A2 (en) * 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Method of characterizing vascular diseases

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629147A (en) 1992-07-17 1997-05-13 Aprogenex, Inc. Enriching and identifying fetal cells in maternal blood for in situ hybridization
US5432054A (en) 1994-01-31 1995-07-11 Applied Imaging Method for separating rare cells from a population of cells
US20050123938A1 (en) * 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
WO2000040749A2 (en) * 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
US20080009467A1 (en) 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US6727066B2 (en) 2000-07-28 2004-04-27 Incyte Corporation Genes expressed in treated human C3A liver cell cultures
US6664056B2 (en) * 2000-10-17 2003-12-16 The Chinese University Of Hong Kong Non-invasive prenatal monitoring
WO2003095624A2 (en) 2002-05-10 2003-11-20 Phase-1 Molecular Toxicology, Inc. Liver inflammation predictive genes
AU2003272204A1 (en) 2002-07-12 2004-02-02 The Johns Hopkins University Neuronal and retinal gene expression patterns
WO2004007673A2 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Neuronal gene expression patterns
US20060003342A1 (en) * 2004-01-15 2006-01-05 Bianchi Diana W Fetal RNA in amniotic fluid to determine gene expression in the developing fetus
JP2008515384A (en) * 2004-07-21 2008-05-15 ザ・レジェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア Salivary transcriptome diagnosis
US7713693B1 (en) * 2004-09-01 2010-05-11 University Of Louisiana At Monroe Human cancer cell specific gene transcript
US20060166242A1 (en) * 2005-01-06 2006-07-27 Mount Sinai Hospital Markers of pre-term labor
WO2008132752A2 (en) * 2007-05-01 2008-11-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for predicting cancer metastasis
WO2009009457A1 (en) 2007-07-06 2009-01-15 University Of Louisville Research Foundation, Inc. Alzheimer's disease-specific micro-rna microarray and related methods
US8298768B2 (en) * 2007-11-29 2012-10-30 Complete Genomics, Inc. Efficient shotgun sequencing methods
AU2009207291B2 (en) * 2008-01-27 2014-11-06 Mor Research Applications Methods and compositions for diagnosing complications of pregnancy
EP2283155A4 (en) * 2008-05-01 2011-05-11 Swedish Health Services Preterm delivery diagnostic assay
US20110150775A1 (en) * 2008-06-01 2011-06-23 Tufts Medical Center, Inc. Genomic approaches to fetal treatment and diagnosis
US7888030B2 (en) * 2008-08-21 2011-02-15 King's College London Biomarkers
PT2365804E (en) 2008-11-13 2015-09-16 Modgene Llc Reduction of amyloid-beta load in non-brain tissue
JP5917397B2 (en) 2009-09-11 2016-05-11 ザ チャイニーズ ユニバーシティ オブ ホンコン How to evaluate liver lesions
US20120238469A1 (en) * 2009-12-08 2012-09-20 Cedars-Sinai Medical Center Diagnostic biomarker to identify women at risk for preterm delivery
WO2011156763A1 (en) * 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Methods for characterizing kidney function
JP2013531799A (en) * 2010-07-08 2013-08-08 プロノタ エヌ．ヴェ． Biomarkers for hypertension disorders in pregnancy
WO2012012693A2 (en) * 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
US10441577B2 (en) 2011-07-08 2019-10-15 Helmholtz Zentrum Fuer Infektionsforschung Medicament for treatment of liver cancer
EP2742155B1 (en) 2011-08-08 2018-01-24 Advanced Genomic Technology LLC Biomarker for alzheimer's disease and/or mild cognitively impairment
US20140304845A1 (en) 2011-10-31 2014-10-09 Merck Sharp & Dohme Corp. Alzheimer's disease signature markers and methods of use
US20160289762A1 (en) * 2012-01-27 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiliing and quantitating cell-free rna
AU2013211850B8 (en) * 2012-01-27 2017-06-29 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiling and quantitating cell-free RNA
US10054599B2 (en) * 2013-03-12 2018-08-21 Agency For Science, Technology And Research (A*Star) Pre-eclampsia biomarkers
CA2997336A1 (en) 2015-09-14 2017-03-23 Genfit Methods for diagnosing and evaluating non-alcoholic steatohepatitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065629A1 (en) * 2003-01-17 2004-08-05 The Chinese University Of Hong Kong Circulating mrna as diagnostic markers for pregnancy-related disorders
WO2009025852A2 (en) * 2007-08-22 2009-02-26 Xenomics, Inc. Methods of using mirna for detection of in vivo cell death
WO2011156734A2 (en) * 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Method of characterizing vascular diseases

Also Published As

Publication number Publication date
EP3584327A1 (en) 2019-12-25
US20220213549A1 (en) 2022-07-07
US10155986B2 (en) 2018-12-18
JP2017063799A (en) 2017-04-06
US20210363584A1 (en) 2021-11-25
CN108359711A (en) 2018-08-03
WO2013113012A3 (en) 2014-11-06
US20130252835A1 (en) 2013-09-26
SG10201906331TA (en) 2019-08-27
US20190226029A1 (en) 2019-07-25
JP2015511122A (en) 2015-04-16
HK1211624A1 (en) 2016-05-27
US20220042098A1 (en) 2022-02-10
US20220290236A1 (en) 2022-09-15
US20200362416A1 (en) 2020-11-19
WO2013113012A2 (en) 2013-08-01
EP2807277A4 (en) 2016-02-17
AU2013211850B2 (en) 2017-03-02
EP2807277A2 (en) 2014-12-03
US20160017420A1 (en) 2016-01-21
SG11201505515XA (en) 2015-09-29
US20180357379A1 (en) 2018-12-13
AU2013211850B8 (en) 2017-06-29
US20220010381A1 (en) 2022-01-13
CA2863035A1 (en) 2013-08-01
US20170145507A1 (en) 2017-05-25
US10287632B2 (en) 2019-05-14
JP6320302B2 (en) 2018-05-09
US20170145509A1 (en) 2017-05-25
US20200370121A1 (en) 2020-11-26
US20170145508A1 (en) 2017-05-25
CA2863035C (en) 2023-08-29
CN104334742A (en) 2015-02-04
US10240204B2 (en) 2019-03-26
AU2013211850A1 (en) 2014-09-18
US10240200B2 (en) 2019-03-26

Similar Documents

Publication Publication Date Title
AU2013211850A8 (en) Methods for profiling and quantitating cell-free RNA
EA201590027A1 (en) DETECTION METHODS OF DISEASES OR CONDITIONS
EP4306659A3 (en) A method and kit for determining the tissue or cell origin of dna
MX341840B (en) Microrna biomarkers indicative of alzheimer's disease.
GB201200658D0 (en) Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence
EA201390149A1 (en) METHODS FOR DETECTING DISEASES OR PATHOLOGICAL CONDITIONS USING PHAGOCYTARY CELLS
WO2012167142A3 (en) Enzyme quantification
TR201904386T4 (en) Method for detecting nucleosomes containing nucleotides.
NZ608384A (en) Biomarkers of renal injury
GB201216076D0 (en) Methods for obtaining a sequence
WO2013172779A3 (en) Method for indicating the presence or non-presence of prostate cancer
MY170164A (en) Aptamer-based multiplexed assays
EA201400117A1 (en) METHODS AND NUCLEIC ACIDS FOR DETERMINATION OF THE PREDICTION IN CANCER PATIENTS
WO2020055954A3 (en) Methods for detecting liver diseases
BR112014021993B8 (en) "methods for detecting a nucleotide variation in a target nucleic acid sequence by a ptoce assay"
PH12016502411A1 (en) Method for methylation analysis
FR2977674B1 (en) IMPROVED METHOD OF DETECTING AND / OR QUANTIFYING AN ANALYTE PRESENT AT THE SURFACE OF A CELL
GB201206977D0 (en) An enzyme detection device
WO2014060785A3 (en) DIAGNOSTIC METHOD FOR PREDICTING RESPONSE TO TNFα INHIBITOR
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2009149319A3 (en) Gene expression profiles associated with asthma exacerbation attacks
EP2584045A4 (en) Method for detection of colorectal tumor
MX2022013471A (en) Nucleic acid detection and quantification method and compositions.
WO2013112836A3 (en) Diagnostic and prognostic biomarkers for cancer
GB2542576A (en) Method and kit of detecting the absence of micro-oranisms

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ KOH, LIAN CHYE WINSTON; QUAKE, STEPHEN R.; FAN, HEIMUN CHRISTINA AND PAN, WENYING

TH Corrigenda

Free format text: IN VOL 29 , NO 28 , PAGE(S) 4203 UNDER THE HEADING AMENDMENTS - AMENDMENTS MADE UNDER THE NAME BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, APPLICATION NO. 2013211850, UNDER INID (71) CORRECT THE APPLICANT NAME TO THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Free format text: IN VOL 28 , NO 37 , PAGE(S) 4978 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, APPLICATION NO. 2013211850, UNDER INID (71) CORRECT THE APPLICANT NAME TO THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Free format text: IN VOL 31 , NO 8 , PAGE(S) 1257 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, APPLICATION NO. 2013211850, UNDER INID (71) CORRECT THE APPLICANT NAME TO THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 28 JAN 2022 TO 28 JAN 2023 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 28 JAN 2023